The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice
Open accessAbstract
Clinical complications of atherosclerosis arise primarily as a result of luminal obstruction due to atherosclerotic plaque growth, with inadequate outward vessel remodeling and plaque destabilization leading to rupture.IL-1 is a proinflammatory cytokine that promotes atherogenesis in animal models, but its role in plaque destabilization and outward vessel remodeling is unclear.The studies presented herein show that advanced atherosclerotic plaques in mice lacking both IL-1 receptor type I and apolipoprotein E (Il1r1 -/-Apoe -/-mice) unexpectedly exhibited multiple features of plaque instability as compared with those of Il1r1 +/+ Apoe -/-mice.These features included reduced plaque SMC content and coverage, reduced plaque collagen content, and increased intraplaque hemorrhage.In addition, the brachiocephalic arteries of Il1r1 -/-Apoe -/-mice exhibited no difference in plaque size, but reduced vessel area and lumen size relative to controls, demonstrating a reduction in outward vessel remodeling.Interestingly, expression of MMP3 was dramatically reduced within the plaque and vessel wall of Il1r1 -/-Apoe -/-mice, and Mmp3 -/-Apoe -/-mice showed defective outward vessel remodeling compared with controls.In addition, MMP3 was required for IL-1-induced SMC invasion of Matrigel in vitro.Taken together, these results show that IL-1 signaling plays a surprising dual protective role in advanced atherosclerosis by promoting outward vessel remodeling and enhancing features of plaque stability, at least in part through MMP3-dependent mechanisms.Conflict of interest: Gary K. Owens is a shareholder and chief scientific officer of NanoMedical Systems Inc., which develops stent technology unrelated to these studies.Gary K. Owens and Christopher L. Jackson have independently received research funding from AstraZeneca Pharmaceutical Inc. for studies separate from those reported
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Pathophysiology of coronary artery disease
Libby, P., & Theroux, P. (2005) · Circulation · doi:10.1161/circulationaha.105.537878 · Cited by 1,965
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Lack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice
Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Moriwaki, H., & Seishima, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000064374.15232.c3 · Cited by 748
Morphological predictors of arterial remodeling in coronary atherosclerosis
Burke, A. P., Kolodgie, F. D., Farb, A., Weber, D., & Virmani, R. (2002) · Circulation · doi:10.1161/hc0302.102610 · Cited by 525
Clarke, M. C. H., Littlewood, T. D., Figg, N., Maguire, J. J., Davenport, A. P., Goddard, M., & Bennett, M. R. (2008) · Circulation Research · doi:10.1161/circresaha.108.175976 · Cited by 396
Alternatively activated macrophages in infection and autoimmunity
Fairweather, D., & Cihakova, D. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.09.012 · Cited by 290
Belisle, S. E., Tisoncik, J. R., Korth, M. J., Carter, V. S., Proll, S. C., Swayne, D. E., Pantin-Jackwood, M., Tumpey, T. M., & Katze, M. G. (2010) · Journal of Virology · doi:10.1128/jvi.01310-10 · Cited by 70
Cited by
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211
Shankman, L. S., Gomez, D., Cherepanova, O. A., Salmon, M., Alencar, G. F., Haskins, R. M., Swiatlowska, P., Newman, A. A. C., Greene, E. S., Straub, A. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3866 · Cited by 1,218
Self-citationNLRP3 inflammasome in cancer and metabolic diseases
Sharma, B. R., & Kanneganti, T.-D. (2021) · Nature Immunology · doi:10.1038/s41590-021-00886-5 · Cited by 1,097
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
Recent insights into the cellular biology of atherosclerosis
Tabas, I., García-Cardeña, G., & Owens, G. K. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201412052 · Cited by 1,016
Self-citationInterplay between inflammation and thrombosis in cardiovascular pathology
Stark, K., & Massberg, S. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00552-1 · Cited by 1,033
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926
Smooth muscle cell phenotypic switching in atherosclerosis
Gomez, D., & Owens, G. K. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs115 · Cited by 866
Self-citationShankman, L. S., Gomez, D., Cherepanova, O. A., Salmon, M., Alencar, G. F., Haskins, R. M., Swiatlowska, P., Newman, A. A. C., Greene, E. S., Straub, A. C., et al. (2016) · Nature Medicine · doi:10.1038/nm0216-217a · Cited by 764
Self-citationInterleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Kojima, Y., Volkmer, J.-P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., Direnzo, D., Nanda, V., Ye, J., Connolly, A. J., et al. (2016) · Nature · doi:10.1038/nature18935 · Cited by 683
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 619
Ridker, P. M., Howard, C. P., Walter, V., Everett, B., Libby, P., Hensen, J., & Thuren, T. (2012) · Circulation · doi:10.1161/circulationaha.112.122556 · Cited by 530
Inflammation and its Resolution as Determinants of Acute Coronary Syndromes
Libby, P., Tabas, I., Fredman, G., & Fisher, E. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302699 · Cited by 521
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Atherosclerotic Plaque Destabilization: Mechanisms, Models, and Therapeutic Strategies
Silvestre-Roig, C., de Winther, M. P., Weber, C., Daemen, M. J., Lutgens, E., & Soehnlein, O. (2014) · Circulation Research · doi:10.1161/circresaha.114.302355 · Cited by 336
Kawasaki disease: pathophysiology and insights from mouse models
Noval Rivas, M., & Arditi, M. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0426-0 · Cited by 310
Targeting Interleukin-1 in Heart Disease
Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 302
Role of NLRP3 Inflammasomes in Atherosclerosis
Karasawa, T., & Takahashi, M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17001 · Cited by 276
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
“Yet, other recent murine work has suggested that IL-1α and IL-1β may have contrarian atheroprotective effects in advanced lesions in ApoE mice.(24,25)”
BackgroundInflammatory Cell Phenotypes in AAAs: Their Role and Potential as Targets for Therapy
Dale, M. A., Ruhlman, M. K., & Baxter, B. T. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305269 · Cited by 269
KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis
Murgai, M., Ju, W., Eason, M., Kline, J., Beury, D. W., Kaczanowska, S., Miettinen, M. M., Kruhlak, M., Lei, H., Shern, J. F., et al. (2017) · Nature Medicine · doi:10.1038/nm.4400 · Cited by 263
“Of the 8 factors found to be elevated in this assay, WISP1, ANG2 and IL-1ß all have known roles in vascular biology and inflammation, and in some reports can induce KLF4 expression 28–33 .”
Self-citationInterleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice
Gomez, D., Baylis, R. A., Durgin, B. G., Newman, A. A. C., Alencar, G. F., Mahan, S., St. Hilaire, C., Müller, W., Waisman, A., Francis, S. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0124-5 · Cited by 256
Self-citationNon-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice
Bersudsky, M., Luski, L., Fishman, D., White, R. M., Ziv-Sokolovskaya, N., Dotan, S., Rider, P., Kaplanov, I., Aychek, T., Dinarello, C. A., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-303329 · Cited by 252
Activation of the pluripotency factor OCT4 in smooth muscle cells is atheroprotective
Cherepanova, O. A., Gomez, D., Shankman, L. S., Swiatlowska, P., Williams, J., Sarmento, O. F., Alencar, G. F., Hess, D. L., Bevard, M. H., Greene, E. S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4109 · Cited by 221
“Sample size (number of mice) was chosen based on our previous studies 18,29”
InfluentialSelf-citationThe Biological Role of Inflammation in Atherosclerosis
Wong, B. W., Meredith, A., Lin, D., & McManus, B. M. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.06.023 · Cited by 168
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis
Kojima, Y., Downing, K., Kundu, R., Miller, C., Dewey, F., Lancero, H., Raaz, U., Perisic, L., Hedin, U., Schadt, E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70391 · Cited by 148
Vascular Ageing: Mechanisms, Risk Factors, and Treatment Strategies
Ya, J., & Bayraktutan, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411538 · Cited by 57
Zhang, L., Altemus, J., Ding, L., Cherepanova, O., Byzova, T. V., & Podrez, E. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105425 · Cited by 1
“Enhanced Akt3 kinase activity affects pro-in fl ammatory cytokines release from MPMs in a gender-dependent manner Compelling evidence demonstrated the importance of in fl ammation and macrophage cytokines secretion in atherogenesis (16 – 19 , 22 – 25).”
Background
Metadata
- Authors
- Alexander, M. R., Moehle, C. W., Johnson, J. L., Yang, Z., Lee, J. K., Jackson, C. L., & Owens, G. K.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-01-03
- Volume
- 122
- Issue
- 1
- Pages
- 70-79
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2126978153
- Cited by
- 217
- References
- 10
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.